by Maria Zannes | Oct 15, 2020 | Press Releases
Partnership supports patient care and sample collection for automated test demonstrating high accuracy in finding lung cancer FAQ: Answers to Questions about Cypath® Lung October 15, 2020 (San Antonio, TX) bioAffinity Technologies, a privately held biotech company,...
by Maria Zannes | Sep 29, 2020 | Press Releases
SEPTEMBER 29, 2020 (San Antonio, TX) FAQ: Answers to Questions about Cypath® Lung bioAffinity Technologies, a privately-held biotech company, today announced Martin Tammemägi, PhD, Professor Emeritus of Health Sciences at Brock University, will serve as Chairman of...
by Maria Zannes | Aug 12, 2020 | Press Releases
Precision Completes Development of CyPath® Lung and Starts CLIA Validation of Cancer Assay for Sale as a Laboratory Developed Test (LDT) FAQ: Answers to Questions about Cypath® Lung August 12, 2020 (San Antonio, TX) bioAffinity Technologies, a privately-held biotech...
by Maria Zannes | Aug 4, 2020 | Events, Press Releases
AUGUST 4, 2020 (San Antonio, TX) bioAffinity Technologies, a privately held biotech company, today announced its presentation of a poster explaining the Company’s use of flow cytometry for diagnosis of lung disease including cancer at the International Society for...
by Maria Zannes | Jul 28, 2020 | Press Releases
JULY 28, 2020 (San Antonio, TX) bioAffinity Technologies, a privately-held biotech company, today announced it has closed a non-brokered, secured convertible note (“Note”) financing for proceeds of $5,000,000.00 (the “Offering”). The proceeds...
by Maria Zannes | Jul 7, 2020 | Press Releases
OrbiMed Partner and Co-Founder of Alexion increases leadership role in oncology focused private company JULY 7, 2020 (San Antonio, TX) bioAffinity Technologies, a privately-held cancer diagnostics and therapeutics company, today announced that Stephen Squinto, Ph.D.,...
